<SEC-DOCUMENT>0001628280-22-028200.txt : 20221103
<SEC-HEADER>0001628280-22-028200.hdr.sgml : 20221103
<ACCEPTANCE-DATETIME>20221103161446
ACCESSION NUMBER:		0001628280-22-028200
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20221103
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20221103
DATE AS OF CHANGE:		20221103

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cardiff Oncology, Inc.
		CENTRAL INDEX KEY:			0001213037
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				272004382
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35558
		FILM NUMBER:		221358178

	BUSINESS ADDRESS:	
		STREET 1:		11055 FLINTKOTE AVENUE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-952-7570

	MAIL ADDRESS:	
		STREET 1:		11055 FLINTKOTE AVENUE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Trovagene, Inc.
		DATE OF NAME CHANGE:	20130304

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TrovaGene Inc.
		DATE OF NAME CHANGE:	20110830

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XENOMICS INC
		DATE OF NAME CHANGE:	20040719
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>crdf-20221103.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:c1a97d78-1304-4bfa-9963-cec1bf72f473,g:7fef7714-4b4e-4af3-8716-894a5ab47072,d:662d6fbe17d241209f9c7a98515804c3--><html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>crdf-20221103</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i6709d9f13ecc413faa1ab514e8360626_D20221103-20221103" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjY2MmQ2ZmJlMTdkMjQxMjA5ZjljN2E5ODUxNTgwNGMzL3NlYzo2NjJkNmZiZTE3ZDI0MTIwOWY5YzdhOTg1MTU4MDRjM180L2ZyYWc6ZDUzOGZhMjI5YmI5NDc3OGI4YzRhNmQwZTZlNWUyNDAvdGFibGU6MGQyODBmNmE5ZmMxNDJjNjk5YTcwNjgzNDE5MDQ4YzcvdGFibGVyYW5nZTowZDI4MGY2YTlmYzE0MmM2OTlhNzA2ODM0MTkwNDhjN18yLTEtMS0xLTM3Mzg1_b6a72f20-6e71-4b07-b676-2a6e6bf71c1d">0001213037</ix:nonNumeric><ix:nonNumeric contextRef="i6709d9f13ecc413faa1ab514e8360626_D20221103-20221103" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjY2MmQ2ZmJlMTdkMjQxMjA5ZjljN2E5ODUxNTgwNGMzL3NlYzo2NjJkNmZiZTE3ZDI0MTIwOWY5YzdhOTg1MTU4MDRjM180L2ZyYWc6ZDUzOGZhMjI5YmI5NDc3OGI4YzRhNmQwZTZlNWUyNDAvdGFibGU6MGQyODBmNmE5ZmMxNDJjNjk5YTcwNjgzNDE5MDQ4YzcvdGFibGVyYW5nZTowZDI4MGY2YTlmYzE0MmM2OTlhNzA2ODM0MTkwNDhjN18zLTEtMS0xLTM3Mzg1_78fa8eaf-2313-4de2-a642-f7875ae5e285">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="crdf-20221103.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i6709d9f13ecc413faa1ab514e8360626_D20221103-20221103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-03</xbrli:startDate><xbrli:endDate>2022-11-03</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i662d6fbe17d241209f9c7a98515804c3_1"></div><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="i6709d9f13ecc413faa1ab514e8360626_D20221103-20221103" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjY2MmQ2ZmJlMTdkMjQxMjA5ZjljN2E5ODUxNTgwNGMzL3NlYzo2NjJkNmZiZTE3ZDI0MTIwOWY5YzdhOTg1MTU4MDRjM18xL2ZyYWc6YzdkZWYwODc4ZmVkNDJlZjliZWQ4ZTI4NjdjMzI5MTcvdGV4dHJlZ2lvbjpjN2RlZjA4NzhmZWQ0MmVmOWJlZDhlMjg2N2MzMjkxN18yNzY1_97ed535f-2f63-4fb8-b30b-16d91a7f9c8c">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6709d9f13ecc413faa1ab514e8360626_D20221103-20221103" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjY2MmQ2ZmJlMTdkMjQxMjA5ZjljN2E5ODUxNTgwNGMzL3NlYzo2NjJkNmZiZTE3ZDI0MTIwOWY5YzdhOTg1MTU4MDRjM18xL2ZyYWc6YzdkZWYwODc4ZmVkNDJlZjliZWQ4ZTI4NjdjMzI5MTcvdGV4dHJlZ2lvbjpjN2RlZjA4NzhmZWQ0MmVmOWJlZDhlMjg2N2MzMjkxN18yMjg_bb42cda6-5db0-4ad0-9524-c4e4fdeceb3b">November 3, 2022</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><img src="crdf-20221103_g1.jpg" alt="crdf-20221103_g1.jpg" style="height:44px;margin-bottom:5pt;vertical-align:text-bottom;width:157px"/><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6709d9f13ecc413faa1ab514e8360626_D20221103-20221103" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjY2MmQ2ZmJlMTdkMjQxMjA5ZjljN2E5ODUxNTgwNGMzL3NlYzo2NjJkNmZiZTE3ZDI0MTIwOWY5YzdhOTg1MTU4MDRjM18xL2ZyYWc6YzdkZWYwODc4ZmVkNDJlZjliZWQ4ZTI4NjdjMzI5MTcvdGV4dHJlZ2lvbjpjN2RlZjA4NzhmZWQ0MmVmOWJlZDhlMjg2N2MzMjkxN18yNzc2_55179004-18b5-4537-96e3-7178d30d0182">Cardiff Oncology,&#160;Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6709d9f13ecc413faa1ab514e8360626_D20221103-20221103" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjY2MmQ2ZmJlMTdkMjQxMjA5ZjljN2E5ODUxNTgwNGMzL3NlYzo2NjJkNmZiZTE3ZDI0MTIwOWY5YzdhOTg1MTU4MDRjM18xL2ZyYWc6YzdkZWYwODc4ZmVkNDJlZjliZWQ4ZTI4NjdjMzI5MTcvdGFibGU6NTVlNjE1NDc4MWNmNDZlN2JjYjViMGY2ZjQzYmJjYTYvdGFibGVyYW5nZTo1NWU2MTU0NzgxY2Y0NmU3YmNiNWIwZjZmNDNiYmNhNl8wLTAtMS0xLTM3Mzg1_a90b71ba-a343-4f3b-a300-34fa197cb189">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:700;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6709d9f13ecc413faa1ab514e8360626_D20221103-20221103" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjY2MmQ2ZmJlMTdkMjQxMjA5ZjljN2E5ODUxNTgwNGMzL3NlYzo2NjJkNmZiZTE3ZDI0MTIwOWY5YzdhOTg1MTU4MDRjM18xL2ZyYWc6YzdkZWYwODc4ZmVkNDJlZjliZWQ4ZTI4NjdjMzI5MTcvdGFibGU6NTVlNjE1NDc4MWNmNDZlN2JjYjViMGY2ZjQzYmJjYTYvdGFibGVyYW5nZTo1NWU2MTU0NzgxY2Y0NmU3YmNiNWIwZjZmNDNiYmNhNl8wLTEtMS0xLTM3Mzg1_288c6e6c-010d-4733-a80c-4d86e4fbae78">001-35558</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6709d9f13ecc413faa1ab514e8360626_D20221103-20221103" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjY2MmQ2ZmJlMTdkMjQxMjA5ZjljN2E5ODUxNTgwNGMzL3NlYzo2NjJkNmZiZTE3ZDI0MTIwOWY5YzdhOTg1MTU4MDRjM18xL2ZyYWc6YzdkZWYwODc4ZmVkNDJlZjliZWQ4ZTI4NjdjMzI5MTcvdGFibGU6NTVlNjE1NDc4MWNmNDZlN2JjYjViMGY2ZjQzYmJjYTYvdGFibGVyYW5nZTo1NWU2MTU0NzgxY2Y0NmU3YmNiNWIwZjZmNDNiYmNhNl8wLTItMS0xLTM3Mzg1_6485cc60-6ac6-4bac-8191-4f43c198c37a">27-2004382</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IRS Employer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identification No.)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6709d9f13ecc413faa1ab514e8360626_D20221103-20221103" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjY2MmQ2ZmJlMTdkMjQxMjA5ZjljN2E5ODUxNTgwNGMzL3NlYzo2NjJkNmZiZTE3ZDI0MTIwOWY5YzdhOTg1MTU4MDRjM18xL2ZyYWc6YzdkZWYwODc4ZmVkNDJlZjliZWQ4ZTI4NjdjMzI5MTcvdGV4dHJlZ2lvbjpjN2RlZjA4NzhmZWQ0MmVmOWJlZDhlMjg2N2MzMjkxN18yNzc3_2310f338-70e5-4e42-a11b-b7b4e3de491f">11055 Flintkote Avenue</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6709d9f13ecc413faa1ab514e8360626_D20221103-20221103" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjY2MmQ2ZmJlMTdkMjQxMjA5ZjljN2E5ODUxNTgwNGMzL3NlYzo2NjJkNmZiZTE3ZDI0MTIwOWY5YzdhOTg1MTU4MDRjM18xL2ZyYWc6YzdkZWYwODc4ZmVkNDJlZjliZWQ4ZTI4NjdjMzI5MTcvdGV4dHJlZ2lvbjpjN2RlZjA4NzhmZWQ0MmVmOWJlZDhlMjg2N2MzMjkxN18yNzY2_bfdcfcf4-a940-452c-9252-a498bb602f25">San Diego</ix:nonNumeric>, <ix:nonNumeric contextRef="i6709d9f13ecc413faa1ab514e8360626_D20221103-20221103" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjY2MmQ2ZmJlMTdkMjQxMjA5ZjljN2E5ODUxNTgwNGMzL3NlYzo2NjJkNmZiZTE3ZDI0MTIwOWY5YzdhOTg1MTU4MDRjM18xL2ZyYWc6YzdkZWYwODc4ZmVkNDJlZjliZWQ4ZTI4NjdjMzI5MTcvdGV4dHJlZ2lvbjpjN2RlZjA4NzhmZWQ0MmVmOWJlZDhlMjg2N2MzMjkxN18yNzcz_46761c83-716c-4cd3-adc8-6a29a1ae2488">CA</ix:nonNumeric> <ix:nonNumeric contextRef="i6709d9f13ecc413faa1ab514e8360626_D20221103-20221103" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjY2MmQ2ZmJlMTdkMjQxMjA5ZjljN2E5ODUxNTgwNGMzL3NlYzo2NjJkNmZiZTE3ZDI0MTIwOWY5YzdhOTg1MTU4MDRjM18xL2ZyYWc6YzdkZWYwODc4ZmVkNDJlZjliZWQ4ZTI4NjdjMzI5MTcvdGV4dHJlZ2lvbjpjN2RlZjA4NzhmZWQ0MmVmOWJlZDhlMjg2N2MzMjkxN18yNzcw_6aa5ab8e-667b-44de-9d96-89fb7044eec6">92121</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6709d9f13ecc413faa1ab514e8360626_D20221103-20221103" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjY2MmQ2ZmJlMTdkMjQxMjA5ZjljN2E5ODUxNTgwNGMzL3NlYzo2NjJkNmZiZTE3ZDI0MTIwOWY5YzdhOTg1MTU4MDRjM18xL2ZyYWc6YzdkZWYwODc4ZmVkNDJlZjliZWQ4ZTI4NjdjMzI5MTcvdGV4dHJlZ2lvbjpjN2RlZjA4NzhmZWQ0MmVmOWJlZDhlMjg2N2MzMjkxN18yNzY3_90dcc920-8c32-4504-b762-196e5e7b5e9b">(858)</ix:nonNumeric> <ix:nonNumeric contextRef="i6709d9f13ecc413faa1ab514e8360626_D20221103-20221103" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjY2MmQ2ZmJlMTdkMjQxMjA5ZjljN2E5ODUxNTgwNGMzL3NlYzo2NjJkNmZiZTE3ZDI0MTIwOWY5YzdhOTg1MTU4MDRjM18xL2ZyYWc6YzdkZWYwODc4ZmVkNDJlZjliZWQ4ZTI4NjdjMzI5MTcvdGV4dHJlZ2lvbjpjN2RlZjA4NzhmZWQ0MmVmOWJlZDhlMjg2N2MzMjkxN18yNzYz_614a12f4-0f66-4d69-8f3f-878006195dd2">952-7570</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160; </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.140%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.143%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:3pt solid #ffffff;border-top:3pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title&#160;of&#160;each&#160;class:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="border-top:3pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading&#160;Symbol(s)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="border-right:3pt solid #ffffff;border-top:3pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name&#160;of&#160;each&#160;exchange&#160;on&#160;which&#160;registered:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6709d9f13ecc413faa1ab514e8360626_D20221103-20221103" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjY2MmQ2ZmJlMTdkMjQxMjA5ZjljN2E5ODUxNTgwNGMzL3NlYzo2NjJkNmZiZTE3ZDI0MTIwOWY5YzdhOTg1MTU4MDRjM18xL2ZyYWc6YzdkZWYwODc4ZmVkNDJlZjliZWQ4ZTI4NjdjMzI5MTcvdGFibGU6NjM2ZjE0M2E5NDYzNGI5NjkyODBiZjIxOWM3ODNlNWMvdGFibGVyYW5nZTo2MzZmMTQzYTk0NjM0Yjk2OTI4MGJmMjE5Yzc4M2U1Y18xLTAtMS0xLTM3Mzg1_8176a2e9-2b28-406c-89d3-879dbea063de">Common Stock</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6709d9f13ecc413faa1ab514e8360626_D20221103-20221103" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjY2MmQ2ZmJlMTdkMjQxMjA5ZjljN2E5ODUxNTgwNGMzL3NlYzo2NjJkNmZiZTE3ZDI0MTIwOWY5YzdhOTg1MTU4MDRjM18xL2ZyYWc6YzdkZWYwODc4ZmVkNDJlZjliZWQ4ZTI4NjdjMzI5MTcvdGFibGU6NjM2ZjE0M2E5NDYzNGI5NjkyODBiZjIxOWM3ODNlNWMvdGFibGVyYW5nZTo2MzZmMTQzYTk0NjM0Yjk2OTI4MGJmMjE5Yzc4M2U1Y18xLTItMS0xLTM3Mzg1_90a74ca1-62bc-47e6-92dc-f8f1fff93b7c">CRDF</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nasdaq Capital Market</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6709d9f13ecc413faa1ab514e8360626_D20221103-20221103" name="dei:WrittenCommunications" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjY2MmQ2ZmJlMTdkMjQxMjA5ZjljN2E5ODUxNTgwNGMzL3NlYzo2NjJkNmZiZTE3ZDI0MTIwOWY5YzdhOTg1MTU4MDRjM18xL2ZyYWc6YzdkZWYwODc4ZmVkNDJlZjliZWQ4ZTI4NjdjMzI5MTcvdGV4dHJlZ2lvbjpjN2RlZjA4NzhmZWQ0MmVmOWJlZDhlMjg2N2MzMjkxN18yNzcx_86d74b9d-add9-46ef-ae2b-760de0ed10d2">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Written communication pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6709d9f13ecc413faa1ab514e8360626_D20221103-20221103" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjY2MmQ2ZmJlMTdkMjQxMjA5ZjljN2E5ODUxNTgwNGMzL3NlYzo2NjJkNmZiZTE3ZDI0MTIwOWY5YzdhOTg1MTU4MDRjM18xL2ZyYWc6YzdkZWYwODc4ZmVkNDJlZjliZWQ4ZTI4NjdjMzI5MTcvdGV4dHJlZ2lvbjpjN2RlZjA4NzhmZWQ0MmVmOWJlZDhlMjg2N2MzMjkxN18yNzY0_cdbd389e-216f-4824-9837-9cac84b30978">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6709d9f13ecc413faa1ab514e8360626_D20221103-20221103" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjY2MmQ2ZmJlMTdkMjQxMjA5ZjljN2E5ODUxNTgwNGMzL3NlYzo2NjJkNmZiZTE3ZDI0MTIwOWY5YzdhOTg1MTU4MDRjM18xL2ZyYWc6YzdkZWYwODc4ZmVkNDJlZjliZWQ4ZTI4NjdjMzI5MTcvdGV4dHJlZ2lvbjpjN2RlZjA4NzhmZWQ0MmVmOWJlZDhlMjg2N2MzMjkxN18yNzc0_ab1d8805-8192-47bf-9fb1-ca8b3eba683b">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6709d9f13ecc413faa1ab514e8360626_D20221103-20221103" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjY2MmQ2ZmJlMTdkMjQxMjA5ZjljN2E5ODUxNTgwNGMzL3NlYzo2NjJkNmZiZTE3ZDI0MTIwOWY5YzdhOTg1MTU4MDRjM18xL2ZyYWc6YzdkZWYwODc4ZmVkNDJlZjliZWQ4ZTI4NjdjMzI5MTcvdGV4dHJlZ2lvbjpjN2RlZjA4NzhmZWQ0MmVmOWJlZDhlMjg2N2MzMjkxN18yNzcy_311ce9cd-135e-4881-bab4-6287864b5faf">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">&#160;Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).&#160; Emerging growth company&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:138%"><ix:nonNumeric contextRef="i6709d9f13ecc413faa1ab514e8360626_D20221103-20221103" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjY2MmQ2ZmJlMTdkMjQxMjA5ZjljN2E5ODUxNTgwNGMzL3NlYzo2NjJkNmZiZTE3ZDI0MTIwOWY5YzdhOTg1MTU4MDRjM18xL2ZyYWc6YzdkZWYwODc4ZmVkNDJlZjliZWQ4ZTI4NjdjMzI5MTcvdGV4dHJlZ2lvbjpjN2RlZjA4NzhmZWQ0MmVmOWJlZDhlMjg2N2MzMjkxN18yNzY5_ae4e39d9-a984-4466-8bdb-bd0e63f32f8c">o</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:120%">o</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Item 2.02</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:103%">              </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Results of Operations and Financial Conditions.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 3, 2022, Cardiff Oncology, Inc. issued a press release announcing company highlights and financial results for the third quarter ended September 30, 2022.  A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information disclosed under this Item 2.02, including Exhibit 99.1 hereto, is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing.</span></div><div style="text-indent:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01. Financial Statements and Exhibits</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.363%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.437%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="crdf11322-q32022pr.htm">Press Release of Cardiff Oncology, Inc. dated November 3, 2022</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SIGNATURE</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> November 3, 2022</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.704%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.451%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CARDIFF ONCOLOGY,&#160;INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Mark Erlander</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark Erlander</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>crdf11322-q32022pr.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i11ee75cda0ed4bd4a93ac66457cae926_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><img alt="image_0.jpg" src="image_0.jpg" style="height:43px;margin-bottom:5pt;vertical-align:text-bottom;width:159px"></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cardiff Oncology Reports Third Quarter 2022 Results and Provides Business Updates</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8211;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%;padding-left:11.33pt">Data from Phase 1b&#47;2 trial in KRAS-mutated metastatic colorectal cancer (mCRC), per September 12</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.47pt;font-style:italic;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%"> announcement, show durable responses to treatment and support initiation of ONSEMBLE, a randomized Phase 2 trial in KRAS&#47;NRAS-mutated mCRC </font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8211;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%;padding-left:11.33pt">Cash, cash equivalents, and short-term investments of approximately $114 million as of September 30, 2022, provide projected runway into 2025 </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:110%">SAN DIEGO, November 3, 2022 &#8211; Cardiff Oncology, Inc. (Nasdaq&#58; CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced financial results and recent highlights for the third quarter ended September 30, 2022. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8220;We recently announced Phase 1b&#47;2 data that demonstrate onvansertib&#8217;s ability to generate durable responses in KRAS-mutated mCRC patients, with various underlying mutations, when combined with standard-of-care FOLFIRI&#47;bevacizumab. In addition, we observed an increase in objective response rate and progression-free survival in the bevacizumab-na&#239;ve subgroup of patients, providing key learnings to maximize ovansertib&#8217;s therapeutic and commercial potential,&#8221; said Mark Erlander, PhD, chief executive officer of Cardiff Oncology. &#8220;In the fourth quarter we plan to activate ONSEMBLE, a randomized Phase 2 trial in our lead KRAS&#47;NRAS-mutated mCRC program. This trial is designed to corroborate the robust signal of efficacy provided by the Phase 1b&#47;2 results and position onvansertib for a possible accelerated approval opportunity by demonstrating its contribution over standard-of-care alone.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:110%">Dr. Erlander continued, &#8220;With a clear strategic focus and projected cash runway into 2025, we believe we are well positioned to generate value from each of our programs in the coming months and years.&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Recent highlights for the quarter ended September 30, 2022 include&#58; </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">KRAS&#47;NRAS-mutated mCRC Program&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">ONSEMBLE, a Phase 2, open-label, randomized trial for second line treatment of KRAS&#47;NRAS-mutated mCRC, on track for activation in Q4 2022 </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:110%">The Company designed the ONSEMBLE trial to corroborate the robust efficacy signal observed in the Phase 1b&#47;2 trial of onvansertib plus standard-of-care (SoC) FOLFIRI&#47;bevacizumab in second-line KRAS-mutated mCRC, demonstrate onvansertib&#8217;s contribution above SoC alone and confirm the optimal dose. ONSEMBLE is expected to enroll approximately 150 patients who will be randomized 1&#58;1&#58;1 to receive SoC alone, SoC plus 20 mg onvansertib, or SoC plus 30 mg onvansertib, with onvansertib administered on days 1-5 and 15-19 of 28-day treatment cycles. The primary endpoint of the trial is objective response rate (ORR). Progression-free survival (PFS) and duration of response (DoR) will be key secondary endpoints. Activation of the trial is expected in Q4 2022, and topline data are expected in 2H 2024.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Phase 1b&#47;2 mCRC data show durable response to treatment across multiple KRAS-mutation variants, as well as an objective response rate and median progression-free survival that substantially exceed those observed in historical control trials</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:110%">Data from the Phase 1b&#47;2 trial of onvansertib plus FOLFIRI&#47;bevacizumab in second line KRAS-mutated mCRC were presented during the European Society for Medical Oncology (ESMO) Congress 2022 and on a company webcast on September 12, 2022. Key data and conclusions featured in these presentations include&#58;</font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:110%;padding-left:13.8pt">Objective response rate (ORR) across all evaluable patients was 35% (n&#61;48) as compared to an ORR of 5-13% observed historically</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.47pt;font-weight:400;line-height:110%;position:relative;top:-3.48pt;vertical-align:baseline">1-4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:110%">, and the median duration of response (mDoR) across all evaluable patients was 11.7 months </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:110%;padding-left:13.8pt">Median progression-free survival (mPFS) was 9.3 months across all evaluable patients, as compared to mPFS of &#126;4.5 &#8211; 5.7 months observed historically in combination trials that included the standard-of-care FOLFIRI with bevacizumab</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.47pt;font-weight:400;line-height:110%;position:relative;top:-3.48pt;vertical-align:baseline">1-4</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:110%">Subgroup analysis from Phase 1b&#47;2 mCRC trial shows improved ORR and mPFS in bevacizumab na&#239;ve patients</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:110%">A recently reported subgroup analysis from the ongoing Phase 1b&#47;2 clinical trial of onvansertib plus FOLFIRI&#47;bevacizumab in second line KRAS-mutated mCRC showed an ORR of 69% and mPFS of 13.5 months in bevacizumab na&#239;ve patients (n&#61;13). These data compare favorably to historical control trials in mCRC, which show an ORR of approximately 25% and a mPFS of approximately 6.9 months in bevacizumab na&#239;ve patients</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.47pt;font-weight:400;line-height:110%;position:relative;top:-3.48pt;vertical-align:baseline">4-9</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:110%">. The observed increase in ORR in bevacizumab na&#239;ve patients in the Phase 1b&#47;2 trial was seen consistently across all patient characteristics and demographics. Based on these findings, the Company plans to stratify for prior bevacizumab exposure within the randomization of the ONSEMBLE trial and conduct preclinical studies to explore the apparent synergy between onvansertib and bevacizumab.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Data presented at the ESMO conference suggest combining onvansertib with irinotecan (a component of FOLFIRI) overcomes irinotecan-resistance in RAS-mutated mCRC</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:110%">Findings from Cardiff Oncology&#8217;s Expanded Access Program (EAP) of onvansertib in KRAS-mutated mCRC as well as preclinical data from patient-derived xenograft (PDX) models of irinotecan-resistant, RAS-mutated mCRC were featured in a poster at the ESMO Congress 2022. Highlights from the presentation include&#58; </font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:110%;padding-left:13.8pt">EAP patients with prior irinotecan treatment (43 of 51) showed clinical benefit following treatment</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:110%;padding-left:13.8pt">The combination of onvansertib and irinotecan showed significantly greater anti-tumor activity compared to onvansertib monotherapy in 5 of 6 tested PDX models of irinotecan-resistant, RAS-mutated CRC</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:110%">Collectively, these results support the observed mDoR in Cardiff Oncology&#8217;s ongoing Phase 1b&#47;2 trial in KRAS-mutated mCRC and suggest onvansertib may combine with irinotecan to overcome mechanisms driving intrinsic and refractory resistance. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) Program&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Preliminary data provide early signal of efficacy and compare favorably to historical control trials</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:110%">Preliminary data from five evaluable patients in an ongoing open-label Phase 2 trial of onvansertib in combination with nanoliposomal irinotecan and 5-FU in second-line metastatic PDAC showed one patient achieving an initial partial response (PR) and three patients achieving stable disease (SD). Based on prior clinical studies, the historical ORR and mPFS for second-line mPDAC patients are 7.7% and 3.1 months, respectively</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">10,11</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:110%">. All four patients achieving a PR or SD remained on study without disease progression as of the data cut-off date and all have shown tumor shrinkage from baseline. Additional data from the ongoing Phase 2 trial are expected in mid-2023.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%;text-decoration:underline">Investigator-initiated Trials</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Trials in triple negative breast cancer (TNBC) and small cell lung cancer (SCLC) enrolled first patients </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:110%">A single-arm, Phase 1b&#47;2 trial of onvansertib in combination with paclitaxel in patients with unresectable locally advanced or metastatic TNBC recently enrolled its first patient at Dana Farber Cancer Institute (DFCI). Preliminary data from the trial are expected in late 2023 or early 2024. For more information, please visit </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:110%">NCT</font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:110%">0</font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:110%">53</font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:110%">8</font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:110%">3196</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:110%">.</font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:110%">A single-arm, two-stage, Phase 2 trial of onvansertib monotherapy in patients with relapsed SCLC recently enrolled its first patient at the University of Pittsburgh Medical Center (UPMC).</font><font style="background-color:#ffffff;color:#58595b;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:110%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:110%">Preliminary data from the trial are expected in mid-2023. For more information, please visit </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:110%">NCT054509</font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:110%">6</font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:110%">5</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:110%">.</font></div><div style="padding-left:22.5pt;text-indent:-18pt"><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%;text-decoration:underline">Third Quarter 2022 Financial Results&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Liquidity, cash burn and cash runway</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:110%">As of September 30, 2022, Cardiff Oncology had approximately $114 million in cash, cash equivalents, and short-term investments. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:110%">Net cash used in operating activities for the third quarter of 2022 was approximately $7.5 million, an increase of approximately $2.0 million from $5.5 million for the same period in 2021. Based on its current expectations and projections, the Company believes its current cash resources are sufficient to fund its operations into 2025.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Operating Expenses</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</font></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (Decrease)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses&#58;</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,009&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,154&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,855&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,077&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,930&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,086&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,084&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,002&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:110%">The overall increase in research and development expenses was primarily related to chemistry, manufacturing, and controls (&#34;CMC&#34;)&#59; and clinical pharmacology studies to support the development of our lead drug candidate, onvansertib. Salaries and staff costs increased primarily due to additional hires in senior management and our clinical operations team.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:110%">  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:110%">The overall increase in selling, general and administrative expense was primarily due to higher salaries costs from merit increases and additional new hires. An increase in D&#38;O insurance costs also contributed to higher selling, general and administrative expenses in the current period, offset by a reduction in recruiting fees from the prior period. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">References</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.66pt">Giessen et al., Acta Oncologica 2015, 54, 187-193</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.66pt">Cremolini et al., Lancet Oncol 2020, 21, 497&#8211;507</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.66pt">Antoniotti et al., Correspondence Lancet Oncol. June 2020</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.66pt">Bennouna et al., Lancet Oncol. 2013, 14, 29&#8211;37</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.66pt">Hansen et al., Cancers 2021, 13, 1031</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.66pt">Tabernaro et al. Eur J Cancer, 2014, 50, 320-332</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.66pt">Van Cutsem et al., J. Clin. Oncol. 2012, 30,3499&#8211;3506</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.66pt">Tabenaro et al, Lancet Oncol 2015, 16, 499&#8211;508 </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.66pt">Beretta et al., Med Oncol 2013, 30&#58;486</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:4.09pt">Wang-Gillam A, Li C-P, Bodoky G, et al. Lancet 2016, 387&#58;545-57</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:4.09pt">Waters AM, Der CJ. Cold Spring Harb Perspect Med 2018, 8(9)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">About Cardiff Oncology, Inc.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:110%">Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers. Our lead asset is onvansertib, a PLK1 inhibitor we are evaluating in combination with standard-of-care (SoC) therapeutics in clinical programs targeting indications such as KRAS&#47;NRAS-mutated metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC), as well as in investigator-initiated trials in triple negative breast cancer (TNBC) and small cell lung cancer (SCLC). These </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:110%">programs and our broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:110%">https&#58;&#47;&#47;www.cardiffoncology.com.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Forward-Looking Statements</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:110%">Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as &#34;anticipate,&#34; &#34;believe,&#34; &#34;forecast,&#34; &#34;estimated&#34; and &#34;intend&#34; or other similar terms or expressions that concern Cardiff Oncology's expectations, strategy, plans or intentions. These forward-looking statements are based on Cardiff Oncology's current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results&#59; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidate&#59; risks related to business interruptions, including the outbreak of COVID-19 coronavirus, which could seriously harm our financial condition and increase our costs and expenses&#59; uncertainties of government or third party payer reimbursement&#59; dependence on key personnel&#59; limited experience in marketing and sales&#59; substantial competition&#59; uncertainties of patent protection and litigation&#59; dependence upon third parties&#59; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. There are no guarantees that our product candidate will be utilized or prove to be commercially successful. Additionally, there are no guarantees that future clinical trials will be completed or successful or that any precision medicine therapeutics will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in Cardiff Oncology's Form 10-K for the year ended December 31, 2021, and other periodic reports filed with the Securities and Exchange Commission. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Cardiff Oncology does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cardiff Oncology Contact&#58; </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">James Levine </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Chief Financial Officer </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">858-952-7670 </font></div><div><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">jlevine&#64;cardiffoncology.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Investor Contact&#58; </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Joyce Allaire </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">LifeSci Advisors </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">212-915-2569 </font></div><div><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">jallaire&#64;lifesciadvisors.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i11ee75cda0ed4bd4a93ac66457cae926_4"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Cardiff Oncology, Inc.</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Condensed Statements of Operations</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">(in thousands, except for per share amounts)</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">(unaudited)</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses&#58;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,009&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,154&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,665&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,552&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,077&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,930&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,103&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,003&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,086&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,084&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,768&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,555&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,993)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,998)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,510)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,329)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">841&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) from change in fair value of derivative financial instruments&#8212;warrants</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(338)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss </font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,571)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,913)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,007)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,849)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock dividend</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,577)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,919)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,025)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,867)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share &#8212; basic and diluted</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.20)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.17)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.69)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.49)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8212; basic and diluted</font></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,333&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,552&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,291&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,501&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div id="i11ee75cda0ed4bd4a93ac66457cae926_7"></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Cardiff Oncology, Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Condensed Balance Sheets</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">(in thousands)</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">(unaudited)</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.590%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.691%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,717&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,943&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,586&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,878&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable and unbilled receivable</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,802&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,771&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,755&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,127&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,304&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,388&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,796&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,631&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,544&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities and Stockholders&#8217; Equity</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,425&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,439&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,138&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,527&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,245&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,559&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,174&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,568&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,419&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,127&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,212&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,417&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,631&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,544&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div id="i11ee75cda0ed4bd4a93ac66457cae926_10"></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Cardiff Oncology, Inc.</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Condensed Statements of Cash Flows</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">(in thousands)</font></div><div style="padding-left:9pt;padding-right:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:174%">(unaudited)</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,007)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,849)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal of fixed assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,244&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,244&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of premiums on short-term investments</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,160&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative financial instruments&#8212;warrants</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(280)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Release of clinical trial funding commitment</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,505&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,372&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,769)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,430)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,650)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net capital expenditures</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(817)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net purchases, maturities and sales of short-term investments</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,946&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122,556)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,129&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122,654)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales of common stock, net of expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,225&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of options</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of warrants</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,263&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,488&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,774&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(117,816)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents&#8212;Beginning of period</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,943&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,981&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents&#8212;End of period</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,717&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,165&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>crdf-20221103.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:c1a97d78-1304-4bfa-9963-cec1bf72f473,g:7fef7714-4b4e-4af3-8716-894a5ab47072-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:crdf="http://www.cardiffoncology.com/20221103" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cardiffoncology.com/20221103">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crdf-20221103_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crdf-20221103_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.cardiffoncology.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>crdf-20221103_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:c1a97d78-1304-4bfa-9963-cec1bf72f473,g:7fef7714-4b4e-4af3-8716-894a5ab47072-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_ef33af66-2eb4-4fc6-97f6-23e577e50b8f_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_b973dd44-31e1-4328-9733-069fa5f7f158_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_d78a7a21-85d6-4a0c-b881-164939cc6a3e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_a56a16b5-0b4a-4dc1-b4be-79b74cf9de11_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_1e36fedc-a95c-4e75-adb7-ae6a50631c21_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_653091fe-29c5-4955-95c6-dab55c1c7ce8_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_d02331ca-5197-4775-8cf1-39f8d150ace3_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_09ab3a07-52aa-4f28-bc0b-f575eb4da1f7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_ec140c2a-e1d7-4417-84a5-9502dffac958_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_56bcb29b-3976-4a68-b3f4-eec471c5f436_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_3a01e7a8-0f4f-4fe4-9098-ad0ed889a581_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_3e8fcb93-0b6b-4289-a9a6-8540ccb6ac67_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_2d9fd0e7-6faa-4c50-abcc-10dd25474b8a_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_b9b78df1-1267-4fa4-a3c3-7c85d6370c0b_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_5d835c69-58a6-43d1-b9da-1d4d633dc96b_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_9a94f47c-2541-4470-a89a-b37ccce7dfb6_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_6c54708e-fb5d-48e5-ac31-bb5525600300_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_113cd0cc-d583-4dff-813c-216d07f01d73_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_4267e417-e181-4688-8dce-939e90df0aeb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_67ec48a2-f958-46aa-ad89-34554ada9bdb_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_92640396-3c2b-41f9-a824-10a3e37f8cd3_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>crdf-20221103_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:c1a97d78-1304-4bfa-9963-cec1bf72f473,g:7fef7714-4b4e-4af3-8716-894a5ab47072-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/Cover" xlink:type="simple" xlink:href="crdf-20221103.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_516f28c9-6dd2-4c42-a1d9-b42bd0671960" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_46445cbb-ad84-45cd-9401-6fa62bf37bb4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_516f28c9-6dd2-4c42-a1d9-b42bd0671960" xlink:to="loc_dei_DocumentType_46445cbb-ad84-45cd-9401-6fa62bf37bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_b99aa91c-1f40-48d0-a99d-e7bb223a415b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_516f28c9-6dd2-4c42-a1d9-b42bd0671960" xlink:to="loc_dei_DocumentPeriodEndDate_b99aa91c-1f40-48d0-a99d-e7bb223a415b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_6ecc1e62-fc4f-4e3f-be34-791d6b200cd1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_516f28c9-6dd2-4c42-a1d9-b42bd0671960" xlink:to="loc_dei_EntityRegistrantName_6ecc1e62-fc4f-4e3f-be34-791d6b200cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_1f0129a4-939e-437b-ba18-9a339aac2971" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_516f28c9-6dd2-4c42-a1d9-b42bd0671960" xlink:to="loc_dei_EntityFileNumber_1f0129a4-939e-437b-ba18-9a339aac2971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_df577073-6c9b-4d5e-8c71-461f3efb70eb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_516f28c9-6dd2-4c42-a1d9-b42bd0671960" xlink:to="loc_dei_EntityTaxIdentificationNumber_df577073-6c9b-4d5e-8c71-461f3efb70eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_cc12dcea-d045-4123-aa11-73baf79ad456" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_516f28c9-6dd2-4c42-a1d9-b42bd0671960" xlink:to="loc_dei_EntityAddressAddressLine1_cc12dcea-d045-4123-aa11-73baf79ad456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_057f0f85-1c04-4a40-9f42-4b5b4a39b50c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_516f28c9-6dd2-4c42-a1d9-b42bd0671960" xlink:to="loc_dei_EntityAddressStateOrProvince_057f0f85-1c04-4a40-9f42-4b5b4a39b50c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_9a8a648f-17b3-4497-86c2-49d9f83f5cd0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_516f28c9-6dd2-4c42-a1d9-b42bd0671960" xlink:to="loc_dei_EntityAddressPostalZipCode_9a8a648f-17b3-4497-86c2-49d9f83f5cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_3c21c40d-3a88-451b-a26e-35ec75dd3c5f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_516f28c9-6dd2-4c42-a1d9-b42bd0671960" xlink:to="loc_dei_EntityAddressCityOrTown_3c21c40d-3a88-451b-a26e-35ec75dd3c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_c1c1c5be-277d-4258-9211-43b6eb20a2f6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_516f28c9-6dd2-4c42-a1d9-b42bd0671960" xlink:to="loc_dei_CityAreaCode_c1c1c5be-277d-4258-9211-43b6eb20a2f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_1d6b3dad-2924-497b-9fdf-d2a03649ea31" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_516f28c9-6dd2-4c42-a1d9-b42bd0671960" xlink:to="loc_dei_LocalPhoneNumber_1d6b3dad-2924-497b-9fdf-d2a03649ea31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_61dcd337-b973-451c-9694-aebd8463ab86" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_516f28c9-6dd2-4c42-a1d9-b42bd0671960" xlink:to="loc_dei_Security12bTitle_61dcd337-b973-451c-9694-aebd8463ab86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_c58e25a4-73db-414c-8b4e-5f107e2cb52b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_516f28c9-6dd2-4c42-a1d9-b42bd0671960" xlink:to="loc_dei_TradingSymbol_c58e25a4-73db-414c-8b4e-5f107e2cb52b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_fd726ce7-0251-4628-b3ae-5a576df68621" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_516f28c9-6dd2-4c42-a1d9-b42bd0671960" xlink:to="loc_dei_WrittenCommunications_fd726ce7-0251-4628-b3ae-5a576df68621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_0163078e-8f00-4f41-8054-d2a2aa8dbdd2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_516f28c9-6dd2-4c42-a1d9-b42bd0671960" xlink:to="loc_dei_SolicitingMaterial_0163078e-8f00-4f41-8054-d2a2aa8dbdd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_36b55f04-4da8-4c10-9cb1-8acbfa7b2a53" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_516f28c9-6dd2-4c42-a1d9-b42bd0671960" xlink:to="loc_dei_PreCommencementTenderOffer_36b55f04-4da8-4c10-9cb1-8acbfa7b2a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_2b73a169-c25e-4e0c-b0f1-20bff88806c9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_516f28c9-6dd2-4c42-a1d9-b42bd0671960" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_2b73a169-c25e-4e0c-b0f1-20bff88806c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_5daae887-d18c-4f06-a3d7-37375f03b024" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_516f28c9-6dd2-4c42-a1d9-b42bd0671960" xlink:to="loc_dei_EntityEmergingGrowthCompany_5daae887-d18c-4f06-a3d7-37375f03b024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_ceced5f9-674f-4554-a391-3c1b145b57c0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_516f28c9-6dd2-4c42-a1d9-b42bd0671960" xlink:to="loc_dei_EntityIncorporationStateCountryCode_ceced5f9-674f-4554-a391-3c1b145b57c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_fc6fff3e-208e-4639-b660-5917040c4bc3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_516f28c9-6dd2-4c42-a1d9-b42bd0671960" xlink:to="loc_dei_EntityCentralIndexKey_fc6fff3e-208e-4639-b660-5917040c4bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_472e9b1c-75ac-4187-a0b1-3ff922aed079" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_516f28c9-6dd2-4c42-a1d9-b42bd0671960" xlink:to="loc_dei_AmendmentFlag_472e9b1c-75ac-4187-a0b1-3ff922aed079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>crdf-20221103_g1.jpg
<TEXT>
begin 644 crdf-20221103_g1.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  N *8# 2(  A$! Q$!_\0
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M4BI0=TSCE%Q;C)6:"BBBK)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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@MSW-[/"FQ9KF1B\K@=EW'"CLJJ.U=C110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
MB5!.1PT*&@H    -24A$4@  "#P   )$" (   !_LS'E    "7!(67,  40P
M  !9,@$<[ &S  !%KDE$051XG.S<08X<R](FUMZAH)D$S;277HF@#6A56H#F
M)1#W@H^/+&9%97BX?69^#G+4X*LP,_>(C/3OO_T_/@        +\C^H"
M    ?A!:        $806      ! !*$%       006@!      !$$%H
M   1A!8      $ $H04      !!!: $      $006@       !&$%@
M0 2A!0      $$%H 0      1!!:        $806      ! !*$%       0
M06@!      !$$%H        1A!8      $ $H04      !!!: $      $00
M6@       !&$%@      0 2A!0      $$%H 0      1!!:        $806
M      ! !*$%       006@!      !$$%H        1A!8      $ $H04
M     !!!: $      $006@       !&$%@      0 2A!0      $$%H 0
M    1!!:        $806      ! !*$%       006@!      !$$%H
M   1A!8      $ $H04      !!!: $      $006@       !&$%@
M0 2A!0      $$%H 0      1!!:        $806      ! !*$%       0
M06@!      !$$%H        1A!8      $ $H04      !!!: $      $00
M6@       !&$%@      0 2A!0      $$%H 0      1!!:        $806
M      ! !*$%       006@!      !$$%H        1A!8      $ $H04
M     !!!: $      $006@       !&$%@      0 2A!0      $$%H 0
M    1!!:        $806      ! !*$%       006@!      !$$%H
M   1A!8      $ $H04      !!!: $      $006@       !&$%@
M0 2A!0      $$%H 0      1!!:        $806      ! !*$%       0
M06@!      !$$%H        1A!8      $ $H04      !!!: $      $00
M6@       !&$%@      0 2A!0      $$%H 0      1!!:        $806
M      ! !*$%       006A!L?_W?_Z?5S[590(     \#BA!04N!A4R#
M  " HP@MV.=^5B&]       83&C!#D_$%:(+     (!AA!8\Z^FX0G0!
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MEL'G^X-; P     XA-#B%"5G^IN/]4_H$0    !@,*'%$8XZRC^J60    "
M2806PQU[@G]LXP      ?0DMQG)J_V$(      "M""T&*CFICSVL-PT
M@"Z$%M,XH/^4L0      Y!-:S.%<_DM&!     "03&@Q@;/XZTIFU7=<
M   ["2UZ<P3_'G,#      @DM&C,L?M-!@@     $$5HT9+3]H4,$P     @
MA-"B&2?L3RB9Z@F#!0    #X%J%%)P[6'V6\      "UA!8].$_?QIP!
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M     %PDM*CG4'L\2PP     <(70HI[C[!-890    " +PDMZCG+/H2%!@
M  !X36A1S/\!_CDL-     # :T*+8@ZRCV*Y 0    !>$%H4<X1]%*$%
M , +0HMBCK!/8\4!     /Y&:%',$?9IK#@     P-\(+8HYOSZ01?_I__M_
M_M?7G^H" 0   ("MA!:5_!_=G\FB?YE52"\     X$Q"BTI"BS,=N^AO9!6B
M"P     XBM"BDM#B3&>N^_W$0G0!     .,)+2J=>7C-:>N^,*X070    #
M;$*+2J<=7O./<];]H;A"= $     4PDM*IUS>,VO3ECW#7&%W (     YA%:
M5#KA\)H_C5_WG8F%Z (     )A%:5!I_>,VG!J][25PAN@    " ,806E08?
M7O/"R'4OCRM$%P     P@-"BTLC#:[XT;]W+4PJY!0    #,(+2H-._PFBLF
MK7MY."&Z     (!)A!:5)AU><]V,=2\/)$07     #"/T*+2C,-KOJO[NI>'
M$*(+     )A*:%&I^^$U[VF][N79@]P"      836E1J?7C-VYJN>WGD(+H
M    @/&$%I6:'EYS4[MU+X\91!<     < BA1:5VA]<LT6C=RZ,%T04
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M      XAM*@DM#C3U-#B?FU+C&\0      836E026IRI<-T/.= _I$T
MF$=H44EH<:9AH<62F3SAJ&8!    8 :A126AQ9FJUOW,$_PSNP8   " IH06
ME8069QH06JP:Q38G]PX     C0@M*@DMSM0]M%@UA\T.;Q\     6A!:5!):
MG*EO:+%J H4, 0    "2"2TJ"2W.5++N3NI_91H     D$EH44EH<2:A13G3
M     (!,0HM*0HLSM0LM%O:>PT      ()#0HI+0XDQ"BP0& @    "!A!:5
MA!9G$EHD,!      ""2TJ"2T.)/0(H&!     $ @H44EH<69A!8)# 0
M @DM*@DMSB2T2& @     !!(:%%):'$FH44" P$   " 0$*+2D*+,PDM$A@(
M      026E026IQ):)' 0      @D-"BDM#B3$*+! 8"     (&$%I6$%F<2
M6B0P$      ()+2H)+0XD] B@8$     0""A126AQ9F$%@D,!      ""2TJ
M"2W.)+1(8"      $$AH44EH<2:A10(# 0   (! 0HM*0HLS"2T2& @
M!!):5!):G$EHD<!      ""0T**2T.),0HL$!@(     @806E8069Q):)# 0
M      @DM*@DM#B3T"*!@0    ! (*%%):'%F806"0P$      ()+2H)+<XD
MM$A@(      02&A126AQ)J%% @,!    @$!"BTI"BS,)+1(8"      $$EI4
M$EJ<26B1P$      ()#0HI+0XDQ"BP0& @    "!A!:5A!9G$EHD,!
M""2TJ"2T.)/0(H&!     $ @H44EH<69A!8)# 0      @DM*@DMSB2T2& @
M     !!(:%%):'$FH44" P$   " 0$*+2D*+,PDM$A@(      026E026IRI
M9-&=T?_&0      @D-"BDM#B3$*+! 8"     (&$%L6$%J>I2JJ<T?_&0
M   @D-"BF/_8XC1"BQ & @    "!A!;%A!:G$5J$,!      ""2T*';G"%MN
MT4[A<CNC_XV!     $ @H44QH<51A!8Y# 0      @DMBMT\Q99;-%*[T,[H
M?V,@     !!(:%%/:'$(H46..],8.1      ""&TJ.<_MCA!^2H[IO^5:0
M  ! )J%%O?O'V7*+<"'K>_.D?L9AO2$     0#*A102YQ6 YBWO_O+[[J?WA
M[0,   ! /J%%A"7GVJ*+-&G+NBJTZ'AP?W+O     -"(T")%V@$W-P4NZ,*#
M^T;']V=V#0    !-"2U2+#SC%EW42E[*Y2?XR8?X1S4+     #,(+8(L/^P6
M76R6OX)/G.-G'N6?TRD     3"*T"/+$D;?<8H^'UNZ)Y7OH-#_G0']\@P
M   PF- B2Z.S;W[JM6K/G>F7G^P/;@T     #B&TR/+<\;?HX@E-%^OIP_W]
MY_OS.@(   " ,PDMXCR=6X@NEFB]3!N.^'>>\@]K!P    !.)K1(U/I ?+P-
MJ[-A@?8<]#]]UC^C"P    #@)Z%%J!DGX_-,6I=M)_Y/'/JW+AX     ^!NA
M1:X]Y^.BBXM&+L?.H_]5I_\=:P8     +A):Y-IV2BZZ>&WV*O3* 'I5"P
M  !\E] BFMRBW E+L#D)>"\,:%$D     '"3T"+=YD-ST<5/1XU]?R1P/15(
MK@T     6$MHT8/H8J<SIQV8#924)+$     @$)"BS;VGZ2''*;O9,@Y(4%.
M)0    # -D*+3ARI/\IX?RK\3QP*+PT     E!-:].-L?3DC_5-5>""Q
M ("3"2U:*CEDSS]G?X,QOE8>)X@K     . H0HO&'+C?(?BYKCQ:$%<
MP"&$%NTY>7^#H;VA/&805P    # >$*+(9S"7V10=Y3G#1(+     )A-:#%'
MR7%\HQ-Y\UFE/'@05P    # 5$*+:9S+?\I8EBL/(<05     #"/T&(F9_0_
M&<6CR@,)<04     3"*T&*ODL#[JO/[P]K<I3R8D%@     PAM!BN#.CBS.[
MKE4>48@K     &  H<41CCK!/ZK9-.(*     . .H<5!QI_FCV_P5__+__5_
M7_GL+TQ< 0    "\36AQEI)C_0TG^R.;^M3%K*(\O9!8 !3ZW_[W_^.]3W7A
M , IO*L \(+0XD23HHM)O;SP=E8Q/KK8W!% "TX! (!D_@\L 'A-:'&N 6?]
M UKXTJJX8EYTL;D+@"ZB3@%..W28<=HRHPL DD6]K@ 02&AQNJ;G_DW+_JXG
M$HN2Z$)<T<+;OQS\BH H(??O(0^-,<_,&5T,L.2[V*( X3S< /B2T()F_S\L
M]:KV;8_&%:VCBYT%S[;J6,1/"TA3?K>>\)08\YR<T45?OHN!,WF: ? EH07_
MR@\#\BM<8EM<T2NZV%GA;-O.1_S,@"JU=^CXA\.,9^.,+OK:]K5KI8!,GF
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M%KRI/'7H$E=\3$DL1!<YRD\N')1 K)(;;<8M/^,1-Z"%1JKVS(R]"AS+4PB
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MMZ27,=-;ZX2Q5/7H0?&0;3VV&&.+(M^N<VVIY07 >X06\,/]T_:.!^YKG3G
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M9'DOY07<ES#&DN(W-)500]_R+IK118BT.RA3^)0"2WI;52^9*YM@V&02VE'
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M9Y$MQA)>9%I5R;-:4N'F^['<^/DLV0]]VX>_$5I 2[**=IYX$2E\+TFKO[R
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M,=YT0H]PG= "H%+YV]NPE\7R!M_NNG"8L:NY1/GJWQ]@[=*$;X_P\BZ:T<4
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MT04 D.F]-XT6+QM]^^I;.>PGM   H),9/_9F= $ 9)H:6O3MJVG94$5H 0!
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MH04  %3R,Q4 >-J>V*#P4SW@_QC0 I036@    # <.6YPOBXXA\SNH!:0@L
M    F*\\8)!8=&D$:@DM     . (Y3'#X,3BPW]F 8L(+0    #@%.5AP\BX
MXL-_9@'K""T     X"SEP<.\(_YA[4 AH04     '*<\?IATOC^O(R@DM
M  " 0Y5'$0,.]Z?V!56$%@    !PNO)DHN^9_NSN8#^A!0    #P0WE0T>Y
M?W9W4$)H 0    #\%T'%12?T")L)+0    " OQ)4 #L)+0    " JT04P*.$
M%@      0 2A!0      $$%H 0      1!!:        $806      ! !*$%
M       006@!      !$$%H        1A!8      $ $H04      !!!: $
M     $006@       !&$%@      0 2A!0      $$%H 0      1!!:
M    $806      ! !*$%       006@!      !$$%H        1A!8
M $ $H04      !!!: $      $006@       !&$%@      0 2A!0
M$$%H 0      1!!:        $806      ! !*$%       006@!      !$
M$%H        1A!8      $ $H04      !!!: $      $006@       !&$
M%@      0 2A!0      $$%H 0      1!!:        $806      ! !*$%
M       006@!      !$$%H        1A!8      $ $H04      !!!: $
M     $006@       !&$%@      0 2A!0      $$%H 0      1!!:
M    $806      ! !*$%       006@!      !$$%H        1A!8
M $ $H04      !!!: $      $006@       !&$%@      0 2A!0
M$$%H 0      1!!:    _W][=BP     ,,C?>AH[2B,  ( %:0$      "Q(
M"P      8$%:        "]("      !8D!8      ,""M        !:D!0
M    L" M      " !6D!       L2 L      &!!6@        O2 @
M6) 6      # @K0        6I 4      + @+0      @ 5I 0      +$@+
M      !@05H        +T@(      %B0%@      P(*T        %J0%
M  "P("T      ( %:0$      "Q("P      8$%:        "]("      !8
MD!8      ,""M        !:D!0      L" M      " !6D!       L2 L
M     &!!6@        O2 @      6) 6      # 0NM#.\ATCB[O     $E%
&3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140312337983120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 03, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  03,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Cardiff Oncology,&#160;Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35558<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-2004382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11055 Flintkote Avenue<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">952-7570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CRDF<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001213037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>crdf-20221103_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="crdf-20221103.xsd" xlink:type="simple"/>
    <context id="i6709d9f13ecc413faa1ab514e8360626_D20221103-20221103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2022-11-03</startDate>
            <endDate>2022-11-03</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i6709d9f13ecc413faa1ab514e8360626_D20221103-20221103"
      id="id3VybDovL2RvY3MudjEvZG9jOjY2MmQ2ZmJlMTdkMjQxMjA5ZjljN2E5ODUxNTgwNGMzL3NlYzo2NjJkNmZiZTE3ZDI0MTIwOWY5YzdhOTg1MTU4MDRjM180L2ZyYWc6ZDUzOGZhMjI5YmI5NDc3OGI4YzRhNmQwZTZlNWUyNDAvdGFibGU6MGQyODBmNmE5ZmMxNDJjNjk5YTcwNjgzNDE5MDQ4YzcvdGFibGVyYW5nZTowZDI4MGY2YTlmYzE0MmM2OTlhNzA2ODM0MTkwNDhjN18yLTEtMS0xLTM3Mzg1_b6a72f20-6e71-4b07-b676-2a6e6bf71c1d">0001213037</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i6709d9f13ecc413faa1ab514e8360626_D20221103-20221103"
      id="id3VybDovL2RvY3MudjEvZG9jOjY2MmQ2ZmJlMTdkMjQxMjA5ZjljN2E5ODUxNTgwNGMzL3NlYzo2NjJkNmZiZTE3ZDI0MTIwOWY5YzdhOTg1MTU4MDRjM180L2ZyYWc6ZDUzOGZhMjI5YmI5NDc3OGI4YzRhNmQwZTZlNWUyNDAvdGFibGU6MGQyODBmNmE5ZmMxNDJjNjk5YTcwNjgzNDE5MDQ4YzcvdGFibGVyYW5nZTowZDI4MGY2YTlmYzE0MmM2OTlhNzA2ODM0MTkwNDhjN18zLTEtMS0xLTM3Mzg1_78fa8eaf-2313-4de2-a642-f7875ae5e285">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i6709d9f13ecc413faa1ab514e8360626_D20221103-20221103"
      id="id3VybDovL2RvY3MudjEvZG9jOjY2MmQ2ZmJlMTdkMjQxMjA5ZjljN2E5ODUxNTgwNGMzL3NlYzo2NjJkNmZiZTE3ZDI0MTIwOWY5YzdhOTg1MTU4MDRjM18xL2ZyYWc6YzdkZWYwODc4ZmVkNDJlZjliZWQ4ZTI4NjdjMzI5MTcvdGV4dHJlZ2lvbjpjN2RlZjA4NzhmZWQ0MmVmOWJlZDhlMjg2N2MzMjkxN18yNzY1_97ed535f-2f63-4fb8-b30b-16d91a7f9c8c">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i6709d9f13ecc413faa1ab514e8360626_D20221103-20221103"
      id="id3VybDovL2RvY3MudjEvZG9jOjY2MmQ2ZmJlMTdkMjQxMjA5ZjljN2E5ODUxNTgwNGMzL3NlYzo2NjJkNmZiZTE3ZDI0MTIwOWY5YzdhOTg1MTU4MDRjM18xL2ZyYWc6YzdkZWYwODc4ZmVkNDJlZjliZWQ4ZTI4NjdjMzI5MTcvdGV4dHJlZ2lvbjpjN2RlZjA4NzhmZWQ0MmVmOWJlZDhlMjg2N2MzMjkxN18yMjg_bb42cda6-5db0-4ad0-9524-c4e4fdeceb3b">2022-11-03</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i6709d9f13ecc413faa1ab514e8360626_D20221103-20221103"
      id="id3VybDovL2RvY3MudjEvZG9jOjY2MmQ2ZmJlMTdkMjQxMjA5ZjljN2E5ODUxNTgwNGMzL3NlYzo2NjJkNmZiZTE3ZDI0MTIwOWY5YzdhOTg1MTU4MDRjM18xL2ZyYWc6YzdkZWYwODc4ZmVkNDJlZjliZWQ4ZTI4NjdjMzI5MTcvdGV4dHJlZ2lvbjpjN2RlZjA4NzhmZWQ0MmVmOWJlZDhlMjg2N2MzMjkxN18yNzc2_55179004-18b5-4537-96e3-7178d30d0182">Cardiff Oncology,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i6709d9f13ecc413faa1ab514e8360626_D20221103-20221103"
      id="id3VybDovL2RvY3MudjEvZG9jOjY2MmQ2ZmJlMTdkMjQxMjA5ZjljN2E5ODUxNTgwNGMzL3NlYzo2NjJkNmZiZTE3ZDI0MTIwOWY5YzdhOTg1MTU4MDRjM18xL2ZyYWc6YzdkZWYwODc4ZmVkNDJlZjliZWQ4ZTI4NjdjMzI5MTcvdGFibGU6NTVlNjE1NDc4MWNmNDZlN2JjYjViMGY2ZjQzYmJjYTYvdGFibGVyYW5nZTo1NWU2MTU0NzgxY2Y0NmU3YmNiNWIwZjZmNDNiYmNhNl8wLTAtMS0xLTM3Mzg1_a90b71ba-a343-4f3b-a300-34fa197cb189">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i6709d9f13ecc413faa1ab514e8360626_D20221103-20221103"
      id="id3VybDovL2RvY3MudjEvZG9jOjY2MmQ2ZmJlMTdkMjQxMjA5ZjljN2E5ODUxNTgwNGMzL3NlYzo2NjJkNmZiZTE3ZDI0MTIwOWY5YzdhOTg1MTU4MDRjM18xL2ZyYWc6YzdkZWYwODc4ZmVkNDJlZjliZWQ4ZTI4NjdjMzI5MTcvdGFibGU6NTVlNjE1NDc4MWNmNDZlN2JjYjViMGY2ZjQzYmJjYTYvdGFibGVyYW5nZTo1NWU2MTU0NzgxY2Y0NmU3YmNiNWIwZjZmNDNiYmNhNl8wLTEtMS0xLTM3Mzg1_288c6e6c-010d-4733-a80c-4d86e4fbae78">001-35558</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i6709d9f13ecc413faa1ab514e8360626_D20221103-20221103"
      id="id3VybDovL2RvY3MudjEvZG9jOjY2MmQ2ZmJlMTdkMjQxMjA5ZjljN2E5ODUxNTgwNGMzL3NlYzo2NjJkNmZiZTE3ZDI0MTIwOWY5YzdhOTg1MTU4MDRjM18xL2ZyYWc6YzdkZWYwODc4ZmVkNDJlZjliZWQ4ZTI4NjdjMzI5MTcvdGFibGU6NTVlNjE1NDc4MWNmNDZlN2JjYjViMGY2ZjQzYmJjYTYvdGFibGVyYW5nZTo1NWU2MTU0NzgxY2Y0NmU3YmNiNWIwZjZmNDNiYmNhNl8wLTItMS0xLTM3Mzg1_6485cc60-6ac6-4bac-8191-4f43c198c37a">27-2004382</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i6709d9f13ecc413faa1ab514e8360626_D20221103-20221103"
      id="id3VybDovL2RvY3MudjEvZG9jOjY2MmQ2ZmJlMTdkMjQxMjA5ZjljN2E5ODUxNTgwNGMzL3NlYzo2NjJkNmZiZTE3ZDI0MTIwOWY5YzdhOTg1MTU4MDRjM18xL2ZyYWc6YzdkZWYwODc4ZmVkNDJlZjliZWQ4ZTI4NjdjMzI5MTcvdGV4dHJlZ2lvbjpjN2RlZjA4NzhmZWQ0MmVmOWJlZDhlMjg2N2MzMjkxN18yNzc3_2310f338-70e5-4e42-a11b-b7b4e3de491f">11055 Flintkote Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i6709d9f13ecc413faa1ab514e8360626_D20221103-20221103"
      id="id3VybDovL2RvY3MudjEvZG9jOjY2MmQ2ZmJlMTdkMjQxMjA5ZjljN2E5ODUxNTgwNGMzL3NlYzo2NjJkNmZiZTE3ZDI0MTIwOWY5YzdhOTg1MTU4MDRjM18xL2ZyYWc6YzdkZWYwODc4ZmVkNDJlZjliZWQ4ZTI4NjdjMzI5MTcvdGV4dHJlZ2lvbjpjN2RlZjA4NzhmZWQ0MmVmOWJlZDhlMjg2N2MzMjkxN18yNzY2_bfdcfcf4-a940-452c-9252-a498bb602f25">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i6709d9f13ecc413faa1ab514e8360626_D20221103-20221103"
      id="id3VybDovL2RvY3MudjEvZG9jOjY2MmQ2ZmJlMTdkMjQxMjA5ZjljN2E5ODUxNTgwNGMzL3NlYzo2NjJkNmZiZTE3ZDI0MTIwOWY5YzdhOTg1MTU4MDRjM18xL2ZyYWc6YzdkZWYwODc4ZmVkNDJlZjliZWQ4ZTI4NjdjMzI5MTcvdGV4dHJlZ2lvbjpjN2RlZjA4NzhmZWQ0MmVmOWJlZDhlMjg2N2MzMjkxN18yNzcz_46761c83-716c-4cd3-adc8-6a29a1ae2488">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i6709d9f13ecc413faa1ab514e8360626_D20221103-20221103"
      id="id3VybDovL2RvY3MudjEvZG9jOjY2MmQ2ZmJlMTdkMjQxMjA5ZjljN2E5ODUxNTgwNGMzL3NlYzo2NjJkNmZiZTE3ZDI0MTIwOWY5YzdhOTg1MTU4MDRjM18xL2ZyYWc6YzdkZWYwODc4ZmVkNDJlZjliZWQ4ZTI4NjdjMzI5MTcvdGV4dHJlZ2lvbjpjN2RlZjA4NzhmZWQ0MmVmOWJlZDhlMjg2N2MzMjkxN18yNzcw_6aa5ab8e-667b-44de-9d96-89fb7044eec6">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i6709d9f13ecc413faa1ab514e8360626_D20221103-20221103"
      id="id3VybDovL2RvY3MudjEvZG9jOjY2MmQ2ZmJlMTdkMjQxMjA5ZjljN2E5ODUxNTgwNGMzL3NlYzo2NjJkNmZiZTE3ZDI0MTIwOWY5YzdhOTg1MTU4MDRjM18xL2ZyYWc6YzdkZWYwODc4ZmVkNDJlZjliZWQ4ZTI4NjdjMzI5MTcvdGV4dHJlZ2lvbjpjN2RlZjA4NzhmZWQ0MmVmOWJlZDhlMjg2N2MzMjkxN18yNzY3_90dcc920-8c32-4504-b762-196e5e7b5e9b">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i6709d9f13ecc413faa1ab514e8360626_D20221103-20221103"
      id="id3VybDovL2RvY3MudjEvZG9jOjY2MmQ2ZmJlMTdkMjQxMjA5ZjljN2E5ODUxNTgwNGMzL3NlYzo2NjJkNmZiZTE3ZDI0MTIwOWY5YzdhOTg1MTU4MDRjM18xL2ZyYWc6YzdkZWYwODc4ZmVkNDJlZjliZWQ4ZTI4NjdjMzI5MTcvdGV4dHJlZ2lvbjpjN2RlZjA4NzhmZWQ0MmVmOWJlZDhlMjg2N2MzMjkxN18yNzYz_614a12f4-0f66-4d69-8f3f-878006195dd2">952-7570</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i6709d9f13ecc413faa1ab514e8360626_D20221103-20221103"
      id="id3VybDovL2RvY3MudjEvZG9jOjY2MmQ2ZmJlMTdkMjQxMjA5ZjljN2E5ODUxNTgwNGMzL3NlYzo2NjJkNmZiZTE3ZDI0MTIwOWY5YzdhOTg1MTU4MDRjM18xL2ZyYWc6YzdkZWYwODc4ZmVkNDJlZjliZWQ4ZTI4NjdjMzI5MTcvdGFibGU6NjM2ZjE0M2E5NDYzNGI5NjkyODBiZjIxOWM3ODNlNWMvdGFibGVyYW5nZTo2MzZmMTQzYTk0NjM0Yjk2OTI4MGJmMjE5Yzc4M2U1Y18xLTAtMS0xLTM3Mzg1_8176a2e9-2b28-406c-89d3-879dbea063de">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i6709d9f13ecc413faa1ab514e8360626_D20221103-20221103"
      id="id3VybDovL2RvY3MudjEvZG9jOjY2MmQ2ZmJlMTdkMjQxMjA5ZjljN2E5ODUxNTgwNGMzL3NlYzo2NjJkNmZiZTE3ZDI0MTIwOWY5YzdhOTg1MTU4MDRjM18xL2ZyYWc6YzdkZWYwODc4ZmVkNDJlZjliZWQ4ZTI4NjdjMzI5MTcvdGFibGU6NjM2ZjE0M2E5NDYzNGI5NjkyODBiZjIxOWM3ODNlNWMvdGFibGVyYW5nZTo2MzZmMTQzYTk0NjM0Yjk2OTI4MGJmMjE5Yzc4M2U1Y18xLTItMS0xLTM3Mzg1_90a74ca1-62bc-47e6-92dc-f8f1fff93b7c">CRDF</dei:TradingSymbol>
    <dei:WrittenCommunications
      contextRef="i6709d9f13ecc413faa1ab514e8360626_D20221103-20221103"
      id="id3VybDovL2RvY3MudjEvZG9jOjY2MmQ2ZmJlMTdkMjQxMjA5ZjljN2E5ODUxNTgwNGMzL3NlYzo2NjJkNmZiZTE3ZDI0MTIwOWY5YzdhOTg1MTU4MDRjM18xL2ZyYWc6YzdkZWYwODc4ZmVkNDJlZjliZWQ4ZTI4NjdjMzI5MTcvdGV4dHJlZ2lvbjpjN2RlZjA4NzhmZWQ0MmVmOWJlZDhlMjg2N2MzMjkxN18yNzcx_86d74b9d-add9-46ef-ae2b-760de0ed10d2">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i6709d9f13ecc413faa1ab514e8360626_D20221103-20221103"
      id="id3VybDovL2RvY3MudjEvZG9jOjY2MmQ2ZmJlMTdkMjQxMjA5ZjljN2E5ODUxNTgwNGMzL3NlYzo2NjJkNmZiZTE3ZDI0MTIwOWY5YzdhOTg1MTU4MDRjM18xL2ZyYWc6YzdkZWYwODc4ZmVkNDJlZjliZWQ4ZTI4NjdjMzI5MTcvdGV4dHJlZ2lvbjpjN2RlZjA4NzhmZWQ0MmVmOWJlZDhlMjg2N2MzMjkxN18yNzY0_cdbd389e-216f-4824-9837-9cac84b30978">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i6709d9f13ecc413faa1ab514e8360626_D20221103-20221103"
      id="id3VybDovL2RvY3MudjEvZG9jOjY2MmQ2ZmJlMTdkMjQxMjA5ZjljN2E5ODUxNTgwNGMzL3NlYzo2NjJkNmZiZTE3ZDI0MTIwOWY5YzdhOTg1MTU4MDRjM18xL2ZyYWc6YzdkZWYwODc4ZmVkNDJlZjliZWQ4ZTI4NjdjMzI5MTcvdGV4dHJlZ2lvbjpjN2RlZjA4NzhmZWQ0MmVmOWJlZDhlMjg2N2MzMjkxN18yNzc0_ab1d8805-8192-47bf-9fb1-ca8b3eba683b">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i6709d9f13ecc413faa1ab514e8360626_D20221103-20221103"
      id="id3VybDovL2RvY3MudjEvZG9jOjY2MmQ2ZmJlMTdkMjQxMjA5ZjljN2E5ODUxNTgwNGMzL3NlYzo2NjJkNmZiZTE3ZDI0MTIwOWY5YzdhOTg1MTU4MDRjM18xL2ZyYWc6YzdkZWYwODc4ZmVkNDJlZjliZWQ4ZTI4NjdjMzI5MTcvdGV4dHJlZ2lvbjpjN2RlZjA4NzhmZWQ0MmVmOWJlZDhlMjg2N2MzMjkxN18yNzcy_311ce9cd-135e-4881-bab4-6287864b5faf">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany
      contextRef="i6709d9f13ecc413faa1ab514e8360626_D20221103-20221103"
      id="id3VybDovL2RvY3MudjEvZG9jOjY2MmQ2ZmJlMTdkMjQxMjA5ZjljN2E5ODUxNTgwNGMzL3NlYzo2NjJkNmZiZTE3ZDI0MTIwOWY5YzdhOTg1MTU4MDRjM18xL2ZyYWc6YzdkZWYwODc4ZmVkNDJlZjliZWQ4ZTI4NjdjMzI5MTcvdGV4dHJlZ2lvbjpjN2RlZjA4NzhmZWQ0MmVmOWJlZDhlMjg2N2MzMjkxN18yNzY5_ae4e39d9-a984-4466-8bdb-bd0e63f32f8c">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M -R/%6RCCAU['JR.\^-_ 5!+ P04    " #6@6-5GZ ;\+$"  #B#   #0
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M?P%02P$"% ,4    " #6@6-5!T%-8H$   "Q    $               @ $
M    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( -:!8U55/ Z5[@   "L"
M   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0
M   ( -:!8U697)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M
M92]T:&5M93$N>&UL4$L! A0#%     @ UH%C57YK1#4;!   V@\  !@
M         ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0
M   ( -:!8U6?H!OPL0(  .(,   -              "  5X,  !X;"]S='EL
M97,N>&UL4$L! A0#%     @ UH%C59>*NQS     $P(   L
M ( !.@\  %]R96QS+RYR96QS4$L! A0#%     @ UH%C5:K$(A8S 0  (@(
M  \              ( !(Q   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (
M -:!8U4D'INBK0   /@!   :              "  8,1  !X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( -:!8U5ED'F2&0$  ,\#   3
M              "  6@2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )
-  D /@(  +(3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>21</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="crdf-20221103.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="crdf-20221103.htm">crdf-20221103.htm</File>
    <File>crdf-20221103.xsd</File>
    <File>crdf-20221103_lab.xml</File>
    <File>crdf-20221103_pre.xml</File>
    <File>crdf11322-q32022pr.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>crdf-20221103_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="21">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "crdf-20221103.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "crdf-20221103.htm"
     ]
    },
    "labelLink": {
     "local": [
      "crdf-20221103_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "crdf-20221103_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "crdf-20221103.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 22,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 21,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "crdf",
   "nsuri": "http://www.cardiffoncology.com/20221103",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221103.htm",
      "contextRef": "i6709d9f13ecc413faa1ab514e8360626_D20221103-20221103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "role": "http://www.cardiffoncology.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221103.htm",
      "contextRef": "i6709d9f13ecc413faa1ab514e8360626_D20221103-20221103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001628280-22-028200-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-22-028200-xbrl.zip
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MM** QC//OL=[/:QPQ-I,T^><-S,O#QY!*X<K?4#E/6?1^_/03<K/(\.4M1J
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MA*F8&<4\S05LF6^:B8L=_6P-. W&+Y@IK2N8BLK3RS\%<@R@A9 2\6L_AO<
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M<K6B&!>B9*8-A9MIBQR._@U02P,$%     @ UH%C5?1N;-OT"0  6UD  !4
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M^0R]UGI^S!V]C?4X2+%8H:PV(<9D0SR,-%VO=Q(_N*S9A@+RTN>'E/WQF&Q
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M^QMA1;ZB[D^21"1J@V\"B0Y#Y32WI]<S$]F660:V^NX#@:(Q)@<2R#@*Z*7
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M_I;6:N:P^4LVJNI%XE0WM;990)RNZ7AA%F""TXZK=/>ZR(.5ZA\IM%[5@!V
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M#TF$]_#56EFPH:"N!BD](6 *RK!=K;/MD,#]SU':D5%7L4?%'NOTF::WMTQ
M[Y\]5H\9NV\05JFFB)WV/7L*_XS"L?/V_P!02P$"% ,4    " #6@6-5(J^*
M'O 3  "5E@  $0              @ $     8W)D9BTR,#(R,3$P,RYH=&U0
M2P$"% ,4    " #6@6-5QN _%FT"  "#!P  $0              @ $?%
M8W)D9BTR,#(R,3$P,RYX<V102P$"% ,4    " #6@6-5I]:K[P,*  "L"@
M%               @ &[%@  8W)D9BTR,#(R,3$P,U]G,2YJ<&=02P$"% ,4
M    " #6@6-5]&YLV_0)  !;60  %0              @ 'P(   8W)D9BTR
M,#(R,3$P,U]L86(N>&UL4$L! A0#%     @ UH%C50/]0QQ\!@  WRX  !4
M             ( !%RL  &-R9&8M,C R,C$Q,#-?<')E+GAM;%!+ 0(4 Q0
M   ( -:!8U5#K7=Y>B@  ,<( @ 6              "  <8Q  !C<F1F,3$S
E,C(M<3,R,#(R<'(N:'1M4$L%!@     &  8 B@$  '1:      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
